PMID- 25126584
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20211021
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2014
DP  - 2014
TI  - Potential and limitation of HLA-based banking of human pluripotent stem cells for 
      cell therapy.
PG  - 518135
LID - 10.1155/2014/518135 [doi]
LID - 518135
AB  - Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. 
      Tissues or organs derived from hPS cells could be the best solution to cure many 
      different human diseases, especially those who do not respond to standard 
      medication or drugs, such as neurodegenerative diseases, heart failure, or 
      diabetes. The origin of hPS is critical and the idea of creating a bank of 
      well-characterized hPS cells has emerged, like the one that already exists for 
      cord blood. However, the main obstacle in transplantation is the rejection of 
      tissues or organ by the receiver, due to the three main immunological barriers: 
      the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The 
      problem could be circumvented by using autologous stem cells, like induced 
      pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells 
      have limitations, especially regarding the disease of the recipient and possible 
      difficulties to handle or prepare autologous iPS cells. Finally, reaching 
      standards of good clinical or manufacturing practices could be challenging. That 
      is why well-characterized and universal hPS cells could be a better solution. In 
      this review, we will discuss the interest and the feasibility to establish hPS 
      cells bank, as well as some economics and ethical issues.
FAU - de Rham, Casimir
AU  - de Rham C
AUID- ORCID: 0000-0002-7448-6432
AD  - Transplant Immunology Unit, Division of Immunology and Allergy and Division of 
      Laboratory Medicine, University Hospital of Geneva, 4 rue Gabrielle 
      Perret-Gentil, 1211 Geneva 14, Switzerland.
FAU - Villard, Jean
AU  - Villard J
AD  - Transplant Immunology Unit, Division of Immunology and Allergy and Division of 
      Laboratory Medicine, University Hospital of Geneva, 4 rue Gabrielle 
      Perret-Gentil, 1211 Geneva 14, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140709
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Cell- and Tissue-Based Therapy
MH  - HLA Antigens/genetics/*immunology
MH  - Haplotypes
MH  - Histocompatibility/genetics/immunology
MH  - Humans
MH  - Pluripotent Stem Cells/*immunology/metabolism
MH  - *Tissue Banks
PMC - PMC4121106
EDAT- 2014/08/16 06:00
MHDA- 2015/05/13 06:00
PMCR- 2014/07/09
CRDT- 2014/08/16 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/06/06 00:00 [revised]
PHST- 2014/06/18 00:00 [accepted]
PHST- 2014/08/16 06:00 [entrez]
PHST- 2014/08/16 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
PHST- 2014/07/09 00:00 [pmc-release]
AID - 10.1155/2014/518135 [doi]
PST - ppublish
SO  - J Immunol Res. 2014;2014:518135. doi: 10.1155/2014/518135. Epub 2014 Jul 9.